Europe moves to reject embattled Duchenne gene therapy
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at…
We’re reading about GLP-1 drugs for addiction, FDA funding
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating,…
FDA focuses attention on rejected drug decisions
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at…
Americans must stop subsidizing the price of drugs in other countries
President Trump is right that Americans often pay too much for prescription drugs, and that other countries aren’t…
Google’s AI company DeepMind launches genetics prediction tool| STAT
Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the…
Nabla raises $70 million as ambient scribe market heats up
Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics.…
FDA denies Barth syndrome drug approval, suggests accelerated pathway
For the past decade, Stealth BioTherapeutics has ridden a rollercoaster trying to convince the Food and Drug Administration…
Civica says study ‘validates’ its model for selling low-cost generics
Five years after launching, a unique nonprofit drug company has published data showing that consumers and health plans…
Scientists call for 10-year ban on CRISPR for germline gene editing
Megan Molteni reports on discoveries from the frontiers of genomic medicine, neuroscience, and reproductive tech. She joined STAT…
We’re reading about Trump drug-pricing plan, obesity drug trial data
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating,…